Get the Stockscreener App
3.03
3.50%
-0.11
Abcellera Biologics Inc stock is traded at $3.03, with a volume of 2.34M.
It is down -3.50% in the last 24 hours and down -0.98% over the past month.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company have extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.
See More
Previous Close:
$3.14
Open:
$3.23
24h Volume:
2.34M
Relative Volume:
0.72
Market Cap:
$894.96M
Revenue:
$38.03M
Net Income/Loss:
$-146.40M
P/E Ratio:
-5.8269
EPS:
-0.52
Net Cash Flow:
$-121.38M
1W Performance:
-7.34%
1M Performance:
-0.98%
6M Performance:
+14.77%
1Y Performance:
-37.01%
1-Day Range:
$3.03
$3.2301
1-Week Range:
$3.03
$3.60
52-Week Range:
$2.335
$5.26
Abcellera Biologics Inc Stock (ABCL) Company Profile
Name
Abcellera Biologics Inc
Sector
Industry
Phone
(604) 559-9005
Address
2215 YUKON STREET, VANCOUVER
Compare ABCL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABCL
Abcellera Biologics Inc
|
3.03 | 894.96M | 38.03M | -146.40M | -121.38M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Feb-22-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Overweight |
| Nov-06-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Oct-13-23 | Resumed | Piper Sandler | Overweight |
| Feb-28-23 | Initiated | Cowen | Outperform |
| Dec-15-22 | Initiated | Goldman | Buy |
| Nov-16-22 | Initiated | Truist | Buy |
| Dec-21-21 | Initiated | The Benchmark Company | Buy |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Jan-05-21 | Initiated | BMO Capital Markets | Outperform |
| Jan-05-21 | Initiated | Berenberg | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Outperform |
| Jan-05-21 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | Stifel | Buy |
View All
Abcellera Biologics Inc Stock (ABCL) Latest News
AbCellera reassigns COO to CTO role, dissolves position - Investing.com India
AbCellera Biologics Changes COO's Title to Technology Chief -February 18, 2025 at 12:57 pm EST - Marketscreener.com
AbCellera reassigns COO to CTO role, dissolves position By Investing.com - Investing.com South Africa
One AbCellera Biologics Insider Raised Their Stake In The Previous Year - Yahoo Finance
Abcellera Biologics, other AI health stocks gain as Ellison touts AI's promise - MSN
AbCellera Biologics Inc. (NASDAQ:ABCL) Short Interest Update - MarketBeat
AbCellera Biologics (ABCL) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
AbCellera Biologics (ABCL) to Release Earnings on Tuesday - MarketBeat
Moloney Securities Asset Management LLC Takes $265,000 Position in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Down 5%Time to Sell? - MarketBeat
AbCellera to Participate at Upcoming Investor Conferences in March - The Globe and Mail
Biotech in B.C. battles harsh market while landing big deals - Business in Vancouver
AbCellera Biologics (NASDAQ:ABCL) Shares Down 4%Here's Why - MarketBeat
AbbVie, AbCellera expand collaboration into T-cell engagers - MSN
ABCL (AbCellera Biologics) Shares Outstanding (EOP) : 295.16 Mil (As of Sep. 2024) - GuruFocus.com
JPMorgan Chase & Co. Acquires 21,483 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics (NASDAQ:ABCL) Shares Up 18.8%Here's What Happened - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 18.8%Here's What Happened - MarketBeat
Abcellera Biologics Inc (ABCL-Q) QuotePress Release - The Globe and Mail
AbCellera to Report Full Year 2024 Financial Results on February 27, 2025 - BioSpace
AbCellera Biologics Inc. (NASDAQ:ABCL) most popular amongst individual investors who own 36% of the shares, institutions hold 29% - Yahoo Finance
AbCellera Biologics (NASDAQ:ABCL) Stock Price Up 10.5%Time to Buy? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6.7%What's Next? - MarketBeat
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 10.5%What's Next? - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Shares Down 6.7%Here's Why - MarketBeat
Geode Capital Management LLC Sells 201,213 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
Geode Capital Management LLC Has $295,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) - MarketBeat
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology - sharewise
AbCellera and AbbVie expand oncology collaboration - Investing.com
AbCellera and AbbVie expand oncology collaboration By Investing.com - Investing.com South Africa
KeyCorp Issues Pessimistic Forecast for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World
AbCellera Biologics (NASDAQ:ABCL) Price Target Cut to $4.00 by Analysts at KeyCorp - MarketBeat
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 7.9%What's Next? - MarketBeat
Is AbCellera Biologics Inc. (ABCL) Among the Best Canadian Penny Stocks to Buy According to Analysts? - Insider Monkey
12 Best Canadian Penny Stocks to Buy According to Analysts - Insider Monkey
AbCellera Biologics (NASDAQ:ABCL) Trading Up 7.2%Time to Buy? - MarketBeat
Stifel Financial Corp Has $195,000 Stock Holdings in AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics (NASDAQ:ABCL) Stock Price Down 6%What's Next? - MarketBeat
Abcellera Biologics Inc Stock (ABCL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):